Using the OMERACT-OARSI criteria, the clinical response of patients presenting with symptomatic hip osteoarthritis (OA) to one intra-articular injection of hylan G-F 20

Clinical response to intra-articular injections of hylan G-F 20 in symptomatic hip osteoarthritis: the OMERACT-OARSI criteria applied to the results of a pilot study.

Article specifications

This clinical trial was published in 2006 in Journal of Joint Bone Spine. (IF 2015: 0.97) by French specialists. The aim of this study was to assess, using the OMERACT-OARSI criteria, the clinical response of patients presenting with symptomatic hip osteoarthritis (OA) to one intra-articular injection of hylan G-F 20. Open-label, multi-centre, prospective, pilot study. Fifty-six patients presenting with primary hip OA, Kellgren-Lawrence grade II-III.

 

Result

In the absence of a control group, the efficacy of the treatment cannot be determined conclusively. Nevertheless, these data suggest that hylan G-F 20 is a symptomatic treatment of hip OA, particularly in less severe radiological cases. A double-blind, controlled study is required to confirm these data.

Tags: France Joint Bone Spine Clinical trial 2006

Hayland Center

© 2018 HYLAND.CENTER ALL RIGHTS RESERVED